Clinical trials data report for Asia-Pacific: Frost & Sullivan collaborates with Novotech

10th March 2020 (Last Updated March 13th, 2020 08:53)

Sponsored by Novotech Sponsored by Visit Company
Clinical trials data report for Asia-Pacific: Frost & Sullivan collaborates with Novotech
According to the clinical trials data report, Asia-Pacific is forecast to record the fastest growth in contract research organisation (CRO) services.

Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments in Asia’s clinical outsourcing landscape. The report highlights the main drivers behind the growth in demand for CRO services in the region.

According to the clinical trials data report, Asia-Pacific is forecast to record the fastest growth in contract research organisation (CRO) services, at almost 15% annually, and will account for 20% of the global CRO market by 2022.

The estimated activity of biotechnology companies in Asia-Pacific has increased more than three times faster in Asia-Pacific compared with the rest of the world between 2016 and 2018.

Trials involving sites in Asia can result in a higher recruitment rate when compared to trials conducted in the United States, especially for complex trials such as in oncology and immuno-oncology. Failure to recruit participants is the main reason for trials missing timelines globally. Sponsors in Europe and North America face challenges around participant recruitment and retention and relatively high costs.

Drivers underlying international demand in Asia-Pacific for clinical research

Large potential participant populations: The clinical trial density (national population divided by the number of recruiting trial sites) is still significantly lower in Asia than in developed markets such as the US. In 2019, Asia accounted for about 60% of the global population.

Greater efficiency of complex clinical trials: For clinical studies initiated in 2018 and 2019, oncology trials involving sites in Asia-Pacific resulted in a higher median recruitment rate and reduced recruitment periods when compared to trials in the US, as well as the worldwide median. Most Asian countries lack systematic reimbursement of oncology and immuno-oncology standards of care, which suggest that clinical trials are often the only channel through which patients can access these treatments, improving treatment adherence and patient recruitment.

Cost efficiencies: Low operational costs position Asia-Pacific as a highly attractive destination for clinical trials when compared with the US and Europe.

Key opinion leaders’ expertise: Asia-Pacific has knowledgeable investigators and experts. Many key opinion leaders are global experts in their fields, and their inclusion in trials is critical.

Novotech: Accelerating clinical trials

Novotech provides regulatory and clinical consulting services to biotechnology companies through its specialised division BioDesk.

BioDesk offers its clients one of the most experienced and cohesive regulatory, CMC and toxicology expert groups available across three continents. To learn more or talk to their experts about your clinical trial, visit Novotech’s website.

Free Whitepaper

The Trends and Future Trajectory of Biotech Clinical Trials

The COVID-19 pandemic has changed the landscape of clinical trials with innumerable vaccines and therapies racing through trials for market or emergency use approval. Looking forward, these changes are projected to accelerate further with innovation shifting from big pharma to biotechs, leading to a greater need for R&D outsourcing.

Data analyst and business intelligence firm GlobalData has partnered with Novotech, the Asia-Pacific CRO, to compile a white paper that explores some of the trends seen in the past year and outline forecasts for what’s next in the industry. With Asia-Pacific expected to have 24% of the global CRO market by 2024, this white paper also explains why the regions is ideal for outsourcing clinical R&D and how drug development plans help biotechs.